Praxis Precision Medicines (PRAX) director granted RSUs and options as equity pay

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Praxis Precision Medicines director Jeffrey Chodakewitz received new equity awards as part of his compensation. He was granted 1,371 restricted stock units, each representing the right to receive one share of common stock, vesting in a single installment on the earlier of June 10, 2027 or the company’s 2027 annual stockholder meeting. He also received options for 648 shares at an exercise price of $240.66 per share, vesting in twelve equal monthly installments starting July 10, 2026 and expiring on June 10, 2036. These are awards from the company, not open-market purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Chodakewitz Jeffrey

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	648	$0.00	--
Grant/Award	Common Stock	1,371	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 648 shares (Direct, null); Common Stock — 1,371 shares (Direct, null)

Footnotes (1)

Dr. Chodakewitz was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

Key Figures

Restricted stock units granted: 1,371 units RSU vesting date: Earlier of June 10, 2027 or 2027 annual meeting Options granted: 648 shares +3 more

6 metrics

Restricted stock units granted 1,371 units Award to Jeffrey Chodakewitz, each for one common share

RSU vesting date Earlier of June 10, 2027 or 2027 annual meeting Single installment vesting condition

Options granted 648 shares Stock Option (Right to Buy) underlying common stock

Option exercise price $240.66 per share Conversion or exercise price for 648 options

Option vesting schedule start July 10, 2026 First of twelve equal monthly installments

Option expiration date June 10, 2036 Final date to exercise granted options

Key Terms

restricted stock units, Stock Option (Right to Buy), exercise price, annual meeting of stockholders, +1 more

5 terms

restricted stock units financial

"Dr. Chodakewitz was awarded 1,371 restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price": "240.6600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual meeting of stockholders financial

"the date of the Issuer's 2027 annual meeting of stockholders."

vest financial

"The shares subject to this option shall vest in twelve (12) equal monthly installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/12/2026 - 05:24 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chodakewitz Jeffrey

(Last)

(First)

(Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON

MASSACHUSETTS

02110

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/10/2026		A⁽¹⁾		1,371	A	$0	1,371	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$240.66	06/10/2026		A		648		⁽²⁾	06/10/2036	Common Stock	648	$0	648	D

Explanation of Responses:

1. Dr. Chodakewitz was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

2. The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Praxis Precision Medicines (PRAX) director Jeffrey Chodakewitz report on this Form 4?

Jeffrey Chodakewitz reported receiving equity awards from Praxis Precision Medicines, including restricted stock units and stock options. These are compensation-related grants, not open-market trades, and increase his potential future ownership in the company if vesting and settlement conditions are met.

How many restricted stock units did Jeffrey Chodakewitz receive from PRAX?

He received 1,371 restricted stock units from Praxis Precision Medicines. Each unit represents a contingent right to receive one share of common stock, with all units vesting together on a single future date tied to either June 10, 2027 or the 2027 annual meeting.

When do Jeffrey Chodakewitz’s PRAX restricted stock units vest?

The 1,371 restricted stock units vest in a single installment on the earlier of June 10, 2027 or the date of Praxis Precision Medicines’ 2027 annual meeting of stockholders. Once vested, they may be settled only by delivering shares of common stock.

What stock options did Jeffrey Chodakewitz receive from Praxis Precision Medicines (PRAX)?

He received options covering 648 shares of Praxis Precision Medicines common stock at an exercise price of $240.66 per share. These options vest in twelve equal monthly installments beginning July 10, 2026 and expire on June 10, 2036 if not exercised.

Are Jeffrey Chodakewitz’s PRAX equity awards open-market purchases or routine grants?

They are routine compensation grants, not open-market purchases. The Form 4 lists the transaction code as a grant or award acquisition, reflecting company-issued restricted stock units and stock options rather than discretionary buying or selling of existing shares.

How will the 648 PRAX stock options granted to Jeffrey Chodakewitz vest over time?

The 648 Praxis Precision Medicines stock options vest in twelve equal monthly installments. Vesting starts on July 10, 2026 and continues until the earlier of June 10, 2027 or the 2027 annual meeting, aligning vesting with the company’s annual governance cycle.